Related Experiment Videos
Clopidogrel: a new antiplatelet drug
R G Lerner1, W H Frishman, K T Mohan
1Division of Hematology, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Heart Disease (Hagerstown, Md.)
|December 1, 2001
Summary
Clopidogrel, a thienopyridine derivative, inhibits platelet aggregation by blocking adenosine diphosphate receptors. This prodrug requires liver metabolism for activation, offering potential advantages in clinical trials, particularly for patients with coronary stents.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Clopidogrel is a novel thienopyridine derivative.
- It functions by inhibiting platelet aggregation via adenosine diphosphate receptor blockade.
- Clopidogrel is administered as a prodrug, necessitating hepatic metabolism to its active form.
Purpose of the Study:
- To review the fundamental chemistry, pharmacodynamics, and pharmacokinetics of clopidogrel.
- To summarize clinical trial data, including its application in patients with coronary stents postangioplasty.
- To assess adverse reactions and compare potential advantages over existing antiplatelet agents.
Main Methods:
- Literature review of clopidogrel's chemical properties.
- Analysis of pharmacodynamic and pharmacokinetic studies.
- Synthesis of data from clinical trials evaluating efficacy and safety.
Main Results:
- Clopidogrel effectively inhibits platelet function.
- The drug is metabolized in the liver to an active metabolite.
- Clinical trials demonstrate its utility, especially in patients with coronary stents, with a summary of adverse events and comparative benefits.
Conclusions:
- Clopidogrel represents a significant advancement in antiplatelet therapy.
- Its mechanism of action and pharmacokinetic profile are well-defined.
- Clinical data support its use in specific cardiovascular indications, highlighting its therapeutic potential and safety profile.